|
Zimvie complaint number (b)(4).D10: eha444, bellatek encode healing abutment 4.1mm(d) x 4.1mm(p) x 4mm(h).D10: eha446, bellatek encode healing abutment 4.1mm(d) x 4.1mm(p) x 6mm(h).The device will not be returned for analysis; however, an investigation of the reported event is in progress.Once the investigation has been completed, a follow-up mdr will be submitted.
|
|
This report is being submitted to relay additional information and device evaluation.The following sections are being reported: b4: date of this report was updated.G3: date received by manufacturer was updated.G6: type of report was updated.H2: type of follow up was updated.H3: device evaluated by manufacturer was updated.H6: type of investigation codes were added: 4109, 4111, 4114 and 3331.H6: investigation findings code was added: 213.H6: investigation conclusions code was added: 4315.H10: narrative/data was updated.Zimvie did not receive the reported implant for evaluation.Visual inspection could not be performed.The investigation has been performed based on the available information using the item number, device history record (dhr) review, and risk management file (rmf).Dhr review was completed for the subject lot number.No deviations or non-conformances, which could have caused or contributed to the reported event, were noted as part of the dhr.Complaint history review was performed for the reported lot number for similar events and 1 other relevant complaint was identified.Based on the investigation and all available information, a definitive root cause could not be determined.However, adherence to the tapping procedure is critical.This step ensures proper implant seating, reduces the required torque, and helps prevent potential damage to the connection, thereby supporting successful placement.Therefore, based on all the available information, device malfunction was not established.Without device receipt, the reported event was non-verifiable.No further investigation or immediate capa / hhe/d escalation is required, as the complaint investigation did not confirm the products were nonconforming at the time of distribution, and no new failure mode, harm, or hazardous situation was identified through the investigation performed.
|